No silly question when it comes to biotech.
To answer your question the Phase I trial will be an "all comers” trial where patients with any cancer type can be included. This should make the trial recruit relatively fast (you are not looking for a specific cancer type) as well as offer the opportunity to even show efficacy given how frequently FTO is overexpressed in cancer.
I don’t think it would be ethical to give healthy people Bisantrene at this stage even at low doses.
Ann: Race investor briefing & updated presentation, page-35
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
